[go: up one dir, main page]

AR104257A1 - Tableta de ribociclib - Google Patents

Tableta de ribociclib

Info

Publication number
AR104257A1
AR104257A1 ARP160101012A ARP160101012A AR104257A1 AR 104257 A1 AR104257 A1 AR 104257A1 AR P160101012 A ARP160101012 A AR P160101012A AR P160101012 A ARP160101012 A AR P160101012A AR 104257 A1 AR104257 A1 AR 104257A1
Authority
AR
Argentina
Prior art keywords
ribociclib
tablet
pharmaceutical tablet
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
ARP160101012A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104257(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR104257A1 publication Critical patent/AR104257A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un comprimido farmacéutico oral que comprende ribociclib o su sal farmacéuticamente aceptable. Reivindicación 2: El comprimido de la reivindicación 1 que comprende succinato de ribociclib. Reivindicación 14: Un comprimido farmacéutico oral recubierto que comprendo ribociclib o su sal farmacéuticamente aceptable en donde el revestimiento comprende polivinil alcohol (PVA). Reivindicación 15: Un comprimido farmacéutico oral recubierto que comprende succinato de ribociclib en el que el recubrimiento comprende PVA.
ARP160101012A 2015-04-16 2016-04-14 Tableta de ribociclib AR104257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16

Publications (1)

Publication Number Publication Date
AR104257A1 true AR104257A1 (es) 2017-07-05

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101012A AR104257A1 (es) 2015-04-16 2016-04-14 Tableta de ribociclib

Country Status (29)

Country Link
US (6) US10799506B2 (es)
EP (3) EP4197530B1 (es)
JP (1) JP2018514523A (es)
KR (2) KR102750931B1 (es)
CN (2) CN107530292B (es)
AR (1) AR104257A1 (es)
AU (5) AU2016248017A1 (es)
BR (1) BR112017021283A2 (es)
CA (1) CA2982425C (es)
CL (1) CL2017002593A1 (es)
CO (1) CO2017010510A2 (es)
DK (1) DK3283058T3 (es)
EA (1) EA201792290A1 (es)
EC (1) ECSP17075052A (es)
ES (1) ES2938261T3 (es)
FI (1) FI3283058T3 (es)
HR (1) HRP20230053T1 (es)
HU (1) HUE061213T2 (es)
IL (1) IL254818A0 (es)
MX (1) MX2017013350A (es)
PE (1) PE20180035A1 (es)
PH (1) PH12017501820A1 (es)
PL (1) PL3283058T3 (es)
PT (1) PT3283058T (es)
SG (1) SG11201708084PA (es)
SI (1) SI3283058T1 (es)
TN (1) TN2017000422A1 (es)
TW (1) TW201642864A (es)
WO (1) WO2016166703A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3283058T3 (fi) * 2015-04-16 2023-03-01 Novartis Ag Ribosiklibitabletti
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
EP4077325A4 (en) 2019-12-16 2023-11-15 Lunella Biotech, Inc. THERAPEUTIC AGENTS SELECTIVE CDK 4/6 INHIBITORS
IL293940A (en) 2019-12-16 2022-08-01 Lunella Biotech Inc Selective cancer drugs cdk4/6 inhibitors
WO2022029798A1 (en) * 2020-08-03 2022-02-10 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
CA3191478A1 (en) * 2020-09-29 2022-04-07 Paola Yazmin Ollervides Rubio Pharmaceutical combinations of statins and fibrates for the treatment and prevention of hyperlipidemias and cardiovascular disease
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
EP4370126A4 (en) 2021-07-16 2025-05-28 Dana-Farber Cancer Institute, Inc. Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
EP4580631A1 (en) 2022-08-31 2025-07-09 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
AU2024244511A1 (en) 2023-03-27 2025-09-25 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
HU225964B1 (en) * 1994-07-12 2008-01-28 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
CN102186856B (zh) 2008-08-22 2014-09-24 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
US8784781B2 (en) * 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
AR083797A1 (es) * 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
JP5898701B2 (ja) * 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
PL2872482T3 (pl) * 2012-07-13 2021-03-08 Oncternal Therapeutics, Inc. Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm)
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
EP2976106B1 (en) * 2013-03-21 2021-04-14 Array BioPharma Inc. Combination therapy comprising a b-raf inhibitor and a second inhibitor
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
FI3283058T3 (fi) 2015-04-16 2023-03-01 Novartis Ag Ribosiklibitabletti
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
FI3283058T3 (fi) 2023-03-01
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
KR102750931B1 (ko) 2025-01-09
EP3283058A1 (en) 2018-02-21
US12064434B2 (en) 2024-08-20
PE20180035A1 (es) 2018-01-09
CN107530292A (zh) 2018-01-02
ECSP17075052A (es) 2018-02-28
AU2022215155A1 (en) 2022-09-01
WO2016166703A1 (en) 2016-10-20
HRP20230053T1 (hr) 2023-03-03
EP4620458A2 (en) 2025-09-24
KR20170137101A (ko) 2017-12-12
US10799506B2 (en) 2020-10-13
US20230104792A1 (en) 2023-04-06
TW201642864A (zh) 2016-12-16
IL254818A0 (en) 2017-12-31
EA201792290A1 (ru) 2018-02-28
EP4620458A3 (en) 2025-10-22
US20250127785A1 (en) 2025-04-24
SG11201708084PA (en) 2017-10-30
HUE061213T2 (hu) 2023-05-28
AU2024227794A1 (en) 2024-11-21
US20200390771A1 (en) 2020-12-17
AU2016248017A1 (en) 2017-10-19
AU2022215155B2 (en) 2024-08-01
ES2938261T3 (es) 2023-04-05
CL2017002593A1 (es) 2018-05-18
PH12017501820A1 (en) 2018-04-23
US20250134893A1 (en) 2025-05-01
CN115554257A (zh) 2023-01-03
AU2020250190A1 (en) 2020-11-05
DK3283058T3 (da) 2023-02-13
CA2982425C (en) 2023-10-31
TN2017000422A1 (en) 2019-01-16
KR20250009572A (ko) 2025-01-17
EP3283058B1 (en) 2022-11-16
CA2982425A1 (en) 2016-10-20
SI3283058T1 (sl) 2023-03-31
EP4197530B1 (en) 2025-11-12
EP4197530A1 (en) 2023-06-21
AU2019201929A1 (en) 2019-04-11
AU2019201929B2 (en) 2020-07-09
JP2018514523A (ja) 2018-06-07
PL3283058T3 (pl) 2023-03-20
PT3283058T (pt) 2023-02-03
CN107530292B (zh) 2022-11-01
CO2017010510A2 (es) 2018-03-20
BR112017021283A2 (pt) 2018-06-26
MX2017013350A (es) 2018-01-25
US20250090531A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
AR104257A1 (es) Tableta de ribociclib
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
CO2019005070A2 (es) Formulaciones farmacéuticas
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
MX2019008302A (es) Inhibidores biciclicos de histona desacetilasa.
UY37941A (es) Derivados de bencimidazol y sus usos
EP3828227A4 (en) POLYVINYL ALCOHOL FILM
EP3630113A4 (en) PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR
EP3868371A4 (en) Novel pharmaceutical composition
UY35000A (es) ?formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa?.
EP3694522A4 (en) TWO-LAYER PHARMACEUTICAL TABLET FORMULATION
AR101860A1 (es) Composición farmacéutica sólida que comprende amlodipina y losartán
EP3697393A4 (en) DOSAGE FORMS
PL3965739T3 (pl) Postacie dawkowane będące tabletkami oleilofosfocholiny
EP4027974C0 (en) PHARMACEUTICAL COMPOSITION CONTAINING P-BORONOPHENYLALANINE
WO2020018053A3 (en) The tablet comprising dasatinib
EP3768248C0 (en) SOLID PHARMACEUTICAL TABLET
EA201891885A1 (ru) Содержащая прегабалин высоконабухаемая трехслойная таблетка с замедленным высвобождением для перорального приема
EP3973940A4 (en) TABLET BOX
CR20190240A (es) Formulaciones farmaceuticas
HK40034195A (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure